C-reactive protein kinetics to predict recurrence of high-risk renal cell carcinoma after radical surgery

被引:2
|
作者
Ishiyama, Yudai [1 ,2 ]
Kondo, Tsunenori [1 ]
Ishihara, Hiroki [1 ]
Yoshida, Kazuhiko [2 ]
Iizuka, Junpei [2 ]
Tanabe, Kazunari [2 ]
Takagi, Toshio [2 ]
机构
[1] Tokyo Womens Med Univ, Dept Urol, Adachi Med Ctr, Adachi Ku, 4-33-1 Kouhoku, Tokyo 1238558, Japan
[2] Tokyo Womens Med Univ, Dept Urol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1620054, Japan
关键词
C-reactive protein; Kidney cancer; Nephrectomy; Recurrence; DISEASE-FREE; SURVIVAL; IMPACT; VALIDATION; LEVEL; PROGNOSIS; NOMOGRAM; THERAPY; MODEL;
D O I
10.1007/s10147-022-02136-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background With new options in adjuvant settings, clinical biomarkers to predict recurrence after radical surgery for high-risk renal cell carcinoma (hrRCC) are in need but are scarcely investigated. We aimed to verify the predictive value of perioperative C-reactive protein (CRP) kinetics on hrRCC recurrence. Methods We retrospectively evaluated 154 patients who underwent radical surgery for hrRCC (>= pT3 and/or N1-2 and M0) at two institutions. Patients were classified into Normal (< 0.5) and High (>= 0.5) according to their preoperative serum CRP (mg/dL). The High group were further classified into Normalized (< 0.5 at post) or Non-normalized (>= 0.5 at post), and recurrence-free survival (RFS) was compared between groups. Factors for RFS were further analysed, and Harrell's concordance index (C-index) for the accuracy of predicting RFS was compared with and without the addition of CRP-related variables to pre-existing models. Results The RFS was significantly shorter in the High (n = 72, 46.8%) compared to the Normal (n = 82, 53.2%) group (9.7 vs. 66.7 months, p < 0.001). Within the High group, Non-normalized (n = 27, 17.5%) patients showed a significantly shorter RFS compared to the Normalized (n = 45, 29.2%) group (6.2 vs. 20.3, p = 0.009). In the multivariable stepwise analysis, CRP kinetics (hazard ratio 2.15, p = 0.029) effectively predicted RFS while baseline CRP fell short of significance. Higher C-index improvement was observed with CRP non-normalization than the baseline value when added to factors in the Karakiewicz and University of California Los Angeles Integrated Staging System models. Conclusions CRP kinetics effectively predicted RCC recurrence after surgery and may aid in decision-making for adjuvant systemic therapy.
引用
收藏
页码:969 / 976
页数:8
相关论文
共 50 条
  • [21] C-Reactive Protein Predicts Acute Myocardial Infarction in High-Risk Noncardiac and Vascular Surgery
    Martins, Oscar M.
    Fonseca, Vicente F.
    Borges, Ivan
    Martins, Valerio
    Guaragna, Joao Carlos
    Portal, Vera L.
    Pellanda, Lucia C.
    CIRCULATION, 2009, 120 (18) : S891 - S891
  • [22] Nomograms incorporating serum C-reactive protein effectively predict mortality before and after surgical treatment of renal cell carcinoma
    Hsiao, Wayland
    Herrel, Lindsey A.
    Yu, Changhong
    Kattan, Michael W.
    Canter, Daniel J.
    Carthon, Bradley C.
    Ogan, Kenneth
    Master, Viraj A.
    INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (03) : 264 - 270
  • [23] UTILITY OF C-REACTIVE PROTEIN LEVELS IN IMPROVING RISK STRATIFICATION IN METASTATIC RENAL CELL CARCINOMA
    Isaac, Ahdoot Aaron
    Margaret, Meagher
    Dhruv, Puri
    Giacomo, Musso
    Kit, Yuen
    Julian, Cortes
    Cesare, Saitta
    Dattatraya, Patil
    Hajime, Tanaka
    Melis, Guer
    Masaki, Kobayashi
    Shohei, Fukuda
    Alberto, Briganti
    Andrea, Salonia
    Umberto, Capitanio
    Alessandro, Larcher
    Francesco, Montorsi
    Yasuhisa, Fujii
    Viraj, Master
    Ithaar, Derweesh
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
  • [24] C-REACTIVE PROTEIN KINETICS ARE ASSOCIATED WITH PROGRESSION AND SURVIVAL IN SURGICALLY TREATED RENAL CELL CARCINOMA PATIENTS
    Cesare, Saitta
    Jonathan, Afari A.
    Kevin, Hakimi
    Luke, Wang
    Kit, Yuen
    Margaret, Meagher
    Franklin, Liu
    Julian, Cortes
    Mirha, Mahmood
    Joshua, Matian
    Mariam, Mansour
    Mimi, Nguyen, V
    Dhruv, Puri
    Clara, Cerrato
    Ava, Saidian
    Ithaar, Derweesh H.
    Hajime, Tanaka
    Masaki, Kobayashi
    Shohei, Fukuda
    Yasuhisa, Fujii
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 : S65 - S65
  • [25] Editorial Comment on: Impact of C-Reactive Protein Kinetics on Survival of Patients with Metastatic Renal Cell Carcinoma
    Novara, Giacomo
    EUROPEAN UROLOGY, 2009, 55 (05) : 1153 - 1154
  • [26] Preoperative c-reactive protein and risk of major complications and mortality outcomes in patients undergoing surgery for renal cell carcinoma.
    Liu, Franklin
    Perry, John M.
    Dhanji, Sohail
    Tanaka, Hajime
    Walia, Arman
    Saidian, Ava
    Narasimhan, Rekha S.
    Nguyen, Mimi
    Hakimi, Kevin
    Wang, Luke
    Afari, Jonathan
    Chakoumakos, Madison
    Meagher, Margaret F.
    Javier-Desloges, Juan
    Saito, Kazutaka
    Fujii, Yasuhisa
    Derweesh, Ithaar
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [27] Minor Symptoms Are Suggestive of Metastatic Renal Cell Carcinoma if C-Reactive Protein Remains High After Curative Nephrectomy
    Abbasi, Ammara
    Johnson, Timothy V.
    Master, Viraj A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (06) : E133 - E134
  • [28] Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma
    Fujikawa, K
    Matsui, Y
    Oka, H
    Fukuzawa, S
    Takeuchi, H
    JOURNAL OF UROLOGY, 1999, 162 (06): : 1934 - 1937
  • [29] Preoperative C-reactive protein/albumin ratio to predict mortality and recurrence of patients with hepatocellular carcinoma after curative resection
    Ren, Yiyue
    Fan, Xiaoxiao
    Chen, Guoqiao
    Zhou, Daizhan
    Lin, Hui
    Cai, Xiujun
    MEDICINA CLINICA, 2019, 153 (05): : 183 - 190
  • [30] Clinicopathological features of recurrence after radical surgery for nonmetastatic renal cell carcinoma
    Ishimura T.
    Sakai I.
    Harada K.-I.
    Hara I.
    Eto H.
    Miyake H.
    International Journal of Clinical Oncology, 2004, 9 (5) : 369 - 372